ArticleMetabolites2020
Characteristic of Metabolic Status in Heart Failure and Its Impact in Outcome Perspective.
Article in Metabolites, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- SERSome-based metabolic profiling of aqueous humor for cataract subtyping with molecule-level interpretability.Journal of nanobiotechnology · 2026Article
- The Use of Metabolomes in Risk Stratification of Patients with Heart Failure: A Scoping Review.Life (Basel, Switzerland) · 2026Review
- Elevated phenylacetylglutamine caused by gut dysbiosis associated with type 2 diabetes increases neutrophil extracellular traps formation and exacerbates brain infarction.Clinical science (London, England : 1979) · 2025Article
- Identification of Chagas disease biomarkers using untargeted metabolomics.Scientific reports · 2024Article
- Review
- Prognostic value of gut microbe-generated metabolite phenylacetylglutamine in patients with heart failure.European journal of heart failure · 2024Article
- Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease: current knowledge and new insights.Frontiers of medicine · 2024Review
- Exploring the impact of metabolites function on heart failure and coronary heart disease: insights from a Mendelian randomization (MR) study.American journal of cardiovascular disease · 2024Article
- Metabolomics Assessment of Volume Overload-Induced Heart Failure and Oxidative Stress in the Kidney.Metabolites · 2023Article
- Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure.ESC heart failure · 2022Article
- Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma.Brain : a journal of neurology · 2022Article
- Effects of Gut Microbiota and Metabolites on Heart Failure and Its Risk Factors: A Two-Sample Mendelian Randomization Study.Frontiers in nutrition · 2022Article
- Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure.Frontiers in cardiovascular medicine · 2022Article
- Dietary Management of Heart Failure: DASH Diet and Precision Nutrition Perspectives.Nutrients · 2021Review
- Plasma amino acid profiling improves predictive accuracy of adverse events in patients with heart failure.ESC heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic alterations have been documented in peripheral tissues in heart failure (HF). Outcomes might be improved by early identification of risk. However, the prognostic information offered is still far from enough. We hypothesized that plasma metabolic profiling potentially provides risk stratification for HF patients. Of 61 patients hospitalized due to acute decompensated HF, 31 developed HF-related events in one year after discharge (Event group), and the other 30 patients did not (Non-event group). The plasma collected during hospital admission was analyzed by an ultra-high performance liquid chromatography time-of-flight mass spectrometry (UPLC-TOFMS)-based metabolomic approach. The orthogonal projection to latent structure discriminant analysis (OPLS-DA) reveals that the metabolomics profile is able to distinguish between events in HF. Levels of 19 metabolites including acylcarnitines, lysophospholipids, dimethylxanthine, dimethyluric acid, tryptophan, phenylacetylglutamine, and hypoxanthine are significantly different between patients with and without event (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.